These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6621997)

  • 21. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
    Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
    J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
    Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radioimmunoassay of prostatic acid phosphatase in serum used "PAP Eiken" kit].
    Hashimoto N; Maruoka Y; Harada M
    Horumon To Rinsho; 1982 Aug; 30(8):869-72. PubMed ID: 7139985
    [No Abstract]   [Full Text] [Related]  

  • 26. Nuclear bone imaging in metastatic cancer of the prostate.
    Pollen JJ; Gerber K; Ashburn WL; Schmidt JD
    Cancer; 1981 Jun; 47(11):2585-94. PubMed ID: 6266636
    [No Abstract]   [Full Text] [Related]  

  • 27. [Improved diagnostic evaluation of prostatic neoplasms using radioimmunoassay for prostatic acid phosphatase].
    Gaca A; Panitz N
    Helv Chir Acta; 1981 Aug; 48(3-4):465-6. PubMed ID: 7287485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of two serum isoenzyme phosphatases as bone metastasis markers].
    Desoize B; Pourny C; Amico S; Larbre H; Jardillier JC
    Bull Cancer; 1990; 77(12):1211-21. PubMed ID: 2081281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
    Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
    Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
    Morote J; de Torres JA
    Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.
    Schaffer DL; Pendergrass HP
    Radiology; 1976 Nov; 121(2):431-4. PubMed ID: 981622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
    Wang ZL; Wang XF
    Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
    Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
    Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
    Nakashima J
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prostatic adenocarcinoma. II. Study of diagnostic methods. Review of the literature].
    Valls Fontanals A; Panadés Nigorra G; Ballester Moll T
    Actas Urol Esp; 1985; 9(2):115-20. PubMed ID: 3893053
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer.
    Gerber G; Chodak GW
    Urology; 1991 May; 37(5):418-22. PubMed ID: 2024388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The diagnostic value of radiological, nuclear medicine and biochemical methods for detection of bone metastases in carcinoma of the prostate (author's transl)].
    Rost A; Fiedler U; Marshall F; Koppenhagen K
    Radiologe; 1977 Jun; 17(6):249-55. PubMed ID: 887744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate tumour markers and differentiation grade in prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Alfthan OS
    Br J Urol; 1990 Dec; 66(6):635-8. PubMed ID: 1702339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.